Similar articles

• Lack of significant effect of therapeutic propranolol on measurable platelet function in healthy subjects.

  Pamphilon DH, Boon RJ, Prentice AG, Rozkovec A. Pamphilon DH, et al. J Clin Pathol. 1989 Aug;42(8):793-6. doi: 10.1136/jcp.42.8.793. J Clin Pathol. 1989. PMID: 2768518 Free PMC article.
• Platelet aggregation in aortic and coronary venous blood in patients with and without coronary disease. 3. Role of tachycardia stress and propranolol.

  Mehta J, Mehta P, Pepine CJ. Mehta J, et al. Circulation. 1978 Nov;58(5):881-6. doi: 10.1161/01.cir.58.5.881. Circulation. 1978. PMID: 699254
• Differences in platelet aggregation in coronary sinus and aortic blood in patients with coronary artery disease: effect of propranolol.

  Mehta J, Mehta P, Pepine CJ. Mehta J, et al. Clin Cardiol. 1978 Aug;1(2):96-100. doi: 10.1002/clc.4960010208. Clin Cardiol. 1978. PMID: 756822
• Current status of platelet inhibitor therapy in coronary artery disease.

  Harbold NB Jr. Harbold NB Jr. Coll Works Cardiopulm Dis. 1982 May;23:1-3. Coll Works Cardiopulm Dis. 1982. PMID: 7047065 Review. No abstract available.
• [Secondary prevention following myocardial infarct. Platelet aggregation inhibitors, beta receptor blockers, antiarrhythmics].

  Schröder R. Schröder R. Dtsch Med Wochenschr. 1981 Apr 24;106(17):546-53. doi: 10.1055/s-2008-1070354. Dtsch Med Wochenschr. 1981. PMID: 6111439 Review. German. No abstract available.